Human papillomavirus testing for cervical cancer screening: Results from a 6-year prospective study in rural China

American Journal of Epidemiology

Volumn 170, Issue 6, 2009, Pages 708-716

  Shi, Ju Fang ^a   Belinson, Jerome L ^b   Zhao, Fang Hui ^a   Pretorius, Robert G ^c   Li, Jing ^a   Ma, Jun Fei ^d   Chen, Feng ^a   Xiang, Wang ^a   Pan, Qin Jing ^a   Zhang, Xun ^a   Zhang, Wen Hua ^a   Qiao, You Lin ^a   Smith, Jennifer S ^e  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Kaiser Permanente ^*  (United States)

^d Xiangyuan Women and Children Hospital   (China)

^e IL   (United States)

Author keywords

Cervical intraepithelial neoplasia; China; Follow up studies; Human papillomavirus; Mass screening

Indexed keywords

VIRUS DNA;

ABNORMALITY; CANCER; COMPARATIVE STUDY; CYTOLOGY; DISEASE INCIDENCE; DISEASE TREATMENT; HEALTH RISK; RURAL AREA; VIRAL DISEASE; WOMENS HEALTH;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CHINA; COLPOSCOPY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; PROSPECTIVE STUDY; RISK ASSESSMENT; RURAL AREA; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHINA; COLPOSCOPY; CONFIDENCE INTERVALS; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; RURAL POPULATION; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

ASIA; CHINA; EURASIA; FAR EAST;

HUMAN PAPILLOMAVIRUS;

EID: 69949152239     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp188     Document Type: Article

References (32)

1. Koliopoulos G, Arbyn M, Martin-Hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007; 104(1): 232-246. (Pubitemid 46054137)
2. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study [electronic article]. BMJ. 2008;337:a1754.
3. Schiller CL, Nickolov AG, Kaul KL, et al. High-risk human papillomavirus detection: a split-sample comparison of hybrid capture and chromogenic in situ hybridization. Am J Clin Pathol. 2004;121(4):537-545. (Pubitemid 38392961)
4. Derchain SF, Sarian LO, Naud P, et al. Safety of screening with human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study. J Med Screen. 2008;15(2):97-104.
5. Gontijo RC, Derchain SF, Roteli-Martins C, et al. Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study. Eur J Obstet Gynecol Reprod Biol. 2007;133(2):239-246. (Pubitemid 47069670)
6. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol. 2008; 168(2): 123-137. (Pubitemid 351951589)
7. Castle PE. Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol. 2008;168(2): 138-144; discussion 145-148.
8. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSILTriage Study. JAMA. 2001;285(11):1500-1505.
9. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83(2):439-444. (Pubitemid 33033096)
10. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999;91(11):954-960.
11. Li N, Shi JF, Franceschi S, et al. Different cervical cancer screening approaches in a Chinese multicentre study. Br J Cancer. 2009;100(3):532-537.
12. Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer. 2002;102(5):519-525. (Pubitemid 35316008)
13. Clavel C, Cucherousset J, Lorenzato M, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer. 2004;90(9): 1803-1808. (Pubitemid 38725657)
14. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol. 2005;58(9):946-950.
15. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1): 46-52.
16. Sherman ME, Castle PE, Solomon D, et al. Cervical cytology of atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer. 2006;108(5):298-305. (Pubitemid 44583708)
17. Safaeian M, Solomon D, Wacholder S, et al. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol. 2007; 109(6): 1325-1331. (Pubitemid 46869871)
18. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354(9172):20-25. (Pubitemid 29304297)
19. Koutsky LA, Holmes KK, Critchlow CW, et al. A. cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992; 327(18):1272-1278.
20. Kim JJ, Kuntz KM, Stout NK, et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol. 2007;166(2):137-150. (Pubitemid 47227293)
21. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):11581171. (Pubitemid 30451948)
22. Saw HS, Lee JK, Lee HL, et al. Natural history of low-grade squamous intraepithelial lesion. J Low Genit Tract Dis. 2001 ; 5(3): 153-158.
23. Melnikow J, Nuovo J, Willan AR, et al. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92(4 pt 2):727-735. (Pubitemid 28440819)
24. Pretorius RG, Belinson JL, Qiao YL, et al. Colposcopy directed biopsy, random biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004; 191 (2):430-434.
25. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26(4):441-446. (Pubitemid 47476331)
26. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100(7): 513-517.
27. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589-1597. (Pubitemid 47598401)
28. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492-501.
29. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370(9601): 1764-1772. (Pubitemid 350137476)
30. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516-520.
31. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-1394.
32. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a crosssectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9(10):929-936.